LIBAR

WithdrawnPhase NA

Liraglutide for Low-responders After Bariatric Surgery

Lead sponsor

Zuyderland Medisch Centrum

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Bariatric Surgery, Obesity / overweight

Eligibility highlights

•BMI ≥35

Primary endpoint

•Body weight, % change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04643301

Org study IDNOK0020

Timeline

Milestones

Study first posted2020-11-25actual

Study start2020-12-21estimated

Last update posted2021-04-26actual

Primary completion2021-12-31estimated

Study completion2021-12-31estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

Bariatric SurgeryObesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•BMI before surgery was ≥ 35.0 kg/m2

•Patient is treated with group consultation at the NOK

•Patient has undergone a primary Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)

•Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module.

Exclusion criteria

•Type 1 or type 2 diabetes

•Decreased renal function (creatinine clearance < 30 ml/min)

•Liver failure (all)

•Congestive heart failure or angina pectoris NYHA class III and IV

•Malignancy in history

•Pancreatitis (in history)

•Pregnancy / breast-feeding

•Inflammatory Bowel Disease

•Thyroid malignancy in history

•Use of warfarin or other coumarin derivates

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

Patient-reported / QoL

Weight & body composition

2 endpoints

Primary/protocol endpoint

%TWL (%TWL)

Time frame:6 months

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

%TWL

Time frame:12, 18, 24 and 36 months

Body weight, % change

percent change from baseline, improvement

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Eating habits

Time frame:6 months

descriptive

Safety / tolerability / PK

3 endpoints

Secondary/protocol endpoint

Persistence

Time frame:6 months

descriptive

Secondary/protocol endpoint

GI symptoms

Time frame:6 months

descriptive

Secondary/protocol endpoint

Dosage in mg

Time frame:6 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.